HOLX vs SPRO · P/E 32, rev $4.10B vs P/E 9.6, rev $48.0M
Hologic Inc (HOLX) versus Spero Therapeutics Inc (SPRO) — a side-by-side from cached financials, not a winner call.
Hologic Inc (HOLX) is a medical instruments & supplies company listed on NASDAQ.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
Latest reported HOLX revenue for 2025-09-27 was $4.10B. Net income was $565.7M. Revenue was up 1.7% from 2024-09-28 to 2025-09-27. HOLX currently screens at market cap $16.97B and trailing P/E 31.5.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
HOLX currently screens at market cap $16.97B and trailing P/E 31.5. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Not investment advice. Open the HOLX and SPRO stock pages for the full models.
Not investment advice.